New scanner aims to measure breast tumors more accurately
NCT ID NCT07492043
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately measure the size of breast tumors in people with ductal carcinoma in situ (DCIS). Twelve participants will receive both a standard MRI and an FCI scan before surgery. The results will be compared to the actual tumor size measured after surgery to see if FCI is reliable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a more accurate way to measure breast tumors without surgery, improving treatment planning.
- What could go wrong
- This is a very small early study (12 people) testing a new imaging technique. It may not prove accurate enough or work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Aberdeen
Aberdeen, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?